Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.68 USD
Change Today -0.0034 / -0.50%
Volume 8.4M
STEM On Other Exchanges
As of 8:10 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

stemcells inc (STEM) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/3/14 - $2.43
52 Week Low
04/24/15 - $0.54
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for STEMCELLS INC (STEM)

stemcells inc (STEM) Related Businessweek News

No Related Businessweek News Found

stemcells inc (STEM) Details

StemCells, Inc., a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development. It engages in clinical development of its platform technology, HuCNS-SC, a purified human neural stem cells used as a potential treatment for disorders of the central nervous system. The company has completed Phase I/II clinical trial for the treatment of chronic spinal cord injury; and Phase I clinical trial for the treatment of Pelizaeus-Merzbacher disease, as well as completed enrollment and treatment in its Phase I/II clinical trial in geographic atrophy of age-related macular degeneration that cause blindness in the elderly. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.

69 Employees
Last Reported Date: 03/13/15
Founded in 1988

stemcells inc (STEM) Top Compensated Officers

Chief Executive Officer, Director, Member of ...
Total Annual Compensation: $789.5K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $607.5K
Executive Vice President of Scientific & Stra...
Total Annual Compensation: $457.3K
General Counsel and Secretary
Total Annual Compensation: $409.6K
Compensation as of Fiscal Year 2014.

stemcells inc (STEM) Key Developments

StemCells Receives Non-Compliance Notice From NASDAQ

On May 14, 2015, StemCells, Inc. received written notice from the Nasdaq Stock Market (Nasdaq) that the closing bid price for the Company’s common stock had been below $1.00 per share for the previous 30 consecutive business days, and that the Company is therefore not in compliance with the requirements for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), StemCells has 180 calendar days, or until November 10, 2015, to regain compliance with this minimum bid price requirement. StemCells can regain compliance with the $1 minimum bid listing requirements of the Nasdaq Capital Market if the closing bid price of the Company’s common stock is $1.00 per share or higher for a minimum of ten consecutive business days during this initial 180-day compliance period. If compliance is not achieved by November 10, 2015, the Company expects that Nasdaq would provide written notification to StemCells that its securities are subject to delisting. StemCells will continue to monitor the closing bid price for its common stock and consider its available options to regain compliance with the Nasdaq minimum bid requirements, which may include applying for an extension of the compliance period or appealing to a Nasdaq Hearings Panel. The Company is continuing to assess its options to maintain the listing of its common stock in light of this recent notification by Nasdaq.

StemCells Inc. Announces Positive Top-Line Results of Its Thoracic Spinal Cord Injury Phase I/II Study

StemCells Inc. announced that Dr. Armin Curt, principal investigator, will present a summary of the safety and preliminary efficacy data from the Phase I/II study investigating Human Central Nervous System Stem Cell (HuCNS-SC) intramedullary transplantation in thoracic spinal cord injury. The international, open-label, Phase I/II trial evaluated both safety and preliminary efficacy of StemCells Inc.'s proprietary HuCNS-SC human neural stem cells as a treatment for chronic spinal cord injury. The trial enrolled twelve patients who had suffered injury to the thoracic cord and were in the early chronic stage of recovery. The severity of spinal cord trauma is classified by the ASIA Impairment Scale (AIS) according to the degree of sensory and motor loss. Patients classified as AIS A, the most severe injury, have lost both sensory and motor function below the level of injury. AIS B patients are considered less severely injured because, although they also have no motor function below the level of injury, some limited sensory function is maintained. The protocol was specifically designed to test safety and preliminary efficacy across this spectrum of injury severity, and ultimately the trial transplanted seven AIS A and five AIS B patients. The analysis of the study demonstrated that the surgical transplantation technique and cell dose were safe and well tolerated by all patients. HuCNS-SC cells were injected directly into the cord both above and below the level of injury and sequential examinations of the patients over the course of twelve months showed no abnormal changes in spinal cord function associated with the transplantation technique. There were no adverse events attributed to the HuCNS-SC cells.

StemCells Inc. Reports Unaudited Consolidated Financial Results for the First Quarter Ended March 31, 2015

StemCells Inc. reported unaudited consolidated financial results for the first quarter ended March 31, 2015. For the first quarter, the company reported revenue from licensing agreements were $21,000 compared to $24,000 a year ago. Loss from operations was $8,960,000 compared to $6,842,000 a year ago. Net loss from continuing operations was $9,351,000 or $0.14 basic and diluted per share compared to $7,562,000 or $0.14 basic and diluted per share a year ago. Net loss was $9,351,000 or $0.14 basic and diluted per share compared to $7,620,000 or $0.14 basic and diluted per share a year ago. Non GAAP net loss was $7,425,000 or $0.11 basic and diluted per share compared to $6,436,000 or $0.12 basic and diluted per share a year ago. The increase of non-GAAP net loss approximately 15% or approximately $1 million is driven by the increase in headcount costs, clinical trial costs and process development activities discussed earlier.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STEM:US $0.68 USD -0.0034

STEM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.36 USD +0.02
Bioheart Inc $0.0052 USD -0.0001
Biorestorative Therapies Inc $0.41 USD -0.024
Cytori Therapeutics Inc $0.67 USD +0.008
IntelliCell BioSciences Inc $0.0002 USD 0.0001
View Industry Companies

Industry Analysis


Industry Average

Valuation STEM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 46.5x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 43.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STEMCELLS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at